Target Name: IL18R1
NCBI ID: G8809
Review Report on IL18R1 Target / Biomarker Content of Review Report on IL18R1 Target / Biomarker
IL18R1
Other Name(s): IL-18R-1 | Interleukin-18 receptor 1 (isoform 2) | Interleukin-18 receptor 1 | IL18RA | IL-1Rrp | IL1 receptor-related protein | interleukin-18 receptor alpha | IL18Ralpha2 | interleukin 18 receptor 1 | IL18R_HUMAN | IL-18R1 | IL-18 receptor 1 | CD218a | IL18R1 variant 2 | IL18R1 variant 1 | IL-18R-alpha | Cytokine receptor | Interleukin-18 receptor 1 (isoform 1) | IL1RRP | Interleukin-18 receptor alpha | CD218 antigen-like family member A | Interleukin 18 receptor 1, transcript variant 1 | cytokine receptor | Interleukin 18 receptor 1, transcript variant 2 | IL1R-rp | IL-18Ralpha | CDw218a

IL-18R1: A Potential Drug Target and Biomarker

The interleukin-18 receptor 1 (IL-18R1) is a protein that plays a crucial role in the immune response and inflammation. It is a member of the IL-18 receptor family, which includes four structurally similar subunits: IL-18R1, IL-18R2, IL-18R3, and IL-18R4.1. IL-18R1 is expressed in various tissues and cells, including immune cells, epithelial cells, and nervous cells. It is involved in the regulation of immune responses, inflammation, and pain.

IL-18R1 is a potential drug target because of its unique structure and its involvement in multiple biological processes. Its unique extracellular domain, which consists of a long amino acid tail, has been identified as a potential drug target. The tail is involved in interactions with other proteins, including the cytokine receptor PD-L1. This interaction suggests that the tail may play a role in modulating the immune response and may be a potential target for small molecules.

In addition to its potential as a drug target, IL-18R1 has also been identified as a potential biomarker for various diseases, including cancer, cardiovascular disease, and neurodegenerative diseases. The expression of IL-18R1 has been observed in various types of cancer, including breast, ovarian, and colorectal cancer. It has also been detected in the brains of individuals with neurodegenerative diseases, such as Alzheimer's and Parkinson's disease.

The identification of IL-18R1 as a potential biomarker for cancer and neurodegenerative diseases has implications for the development of new diagnostic tests and for the development of new treatments. If successful, the development of IL-18R1 as a drug target and biomarker could lead to the development of new treatments for a variety of diseases.

In conclusion, IL-18R1 is a protein that has the potential to be a drug target and biomarker. Its unique structure and its involvement in multiple biological processes make it an attractive target for small molecules. Further research is needed to fully understand the role of IL-18R1 in the immune response and in the regulation of various biological processes. If successful, the development of IL-18R1 as a drug target and biomarker could lead to the development of new treatments for a variety of diseases.

Protein Name: Interleukin 18 Receptor 1

Functions: Within the IL18 receptor complex, responsible for the binding of the pro-inflammatory cytokine IL18, but not IL1A nor IL1B (PubMed:8626725, PubMed:14528293, PubMed:25261253, PubMed:25500532). Involved in IL18-mediated IFNG synthesis from T-helper 1 (Th1) cells (PubMed:10653850). Contributes to IL18-induced cytokine production, either independently of SLC12A3, or as a complex with SLC12A3 (By similarity)

The "IL18R1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL18R1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

IL18RAP | IL19 | IL1A | IL1B | IL1F10 | IL1R1 | IL1R2 | IL1RAP | IL1RAPL1 | IL1RAPL2 | IL1RL1 | IL1RL2 | IL1RN | IL2 | IL20 | IL20RA | IL20RB | IL21 | IL21-AS1 | IL21R | IL21R-AS1 | IL22 | IL22RA1 | IL22RA2 | IL23A | IL23R | IL24 | IL25 | IL26 | IL27 | IL27RA | IL2RA | IL2RB | IL2RG | IL3 | IL31 | IL31RA | IL32 | IL33 | IL34 | IL36A | IL36B | IL36G | IL36RN | IL37 | IL3RA | IL4 | IL4I1 | IL4R | IL5 | IL5RA | IL6 | IL6-AS1 | IL6R | IL6R-AS1 | IL6ST | IL6ST-DT | IL6STP1 | IL7 | IL7R | IL9 | IL9R | IL9RP3 | IL9RP4 | ILDR1 | ILDR2 | ILF2 | ILF3 | ILF3-DT | ILK | ILKAP | ILRUN | ILVBL | Imidazoline I2 receptor (I2) | Imidazoline I3 receptor (I3) | Imidazoline receptor | IMMP1L | IMMP2L | IMMT | IMMTP1 | Immunoglobulin A | Immunoglobulin E (IgE) | Immunoglobulin G | Immunoglobulin M | Immunoglobulin-Like Domain Containing Receptor | Immunoproteasome | IMP3 | IMP4 | IMPA1 | IMPA1P1 | IMPA2 | IMPACT | IMPDH1 | IMPDH1P10 | IMPDH1P6 | IMPDH2 | IMPG1 | IMPG2 | INA | INAFM1